1. Dry AMD and GA: The Present and Future

3. What Is AMD?

4. Clinical Features of AMD

5. Characteristics of Early AMD

6. Characteristics of Intermediate AMD

7. Characteristics of Advanced AMD

8. Pathophysiology of AMD

9. Dry AMD and Atrophy Associated With Increased Lipofuscin/A2E

10. Amyloid Found in Dry AMD

11. Complement Activation in Dry AMD

12. Genetic Correlations Between Complement Cascade and AMD

13. Risk Factors for AMD

14. Symptoms of AMD

15. Diagnosis of AMD

16. Benefit of Supplementation in AMD AREDS Study

17. Evaluation of Further Supplementation AREDS2 Study

18. Current Management in Early AMD

19. Current Management of Intermediate AMD

20. Current Management of Advanced AMD

21. Summary: Dry AMD Treatment in 2016

22. Emerging Therapeutic Strategies in Dry AMD

23. Visual Cycle Modulation

24. Emixustat: Potential Mechanism of Action

25. Phase 2b/3 Trial of Emixustat SEATTLE Study

26. Anti-Amyloid Antibodies

27. Neuroprotection

28. Global Inflammation Suppression

30. Complement Inhibition C5 and C3 Inhibitors

31. Lampalizumab (Anti-Factor D)

32. Phase 2 MAHALO Study of Lampalizumab in GA Secondary to AMD

33. Efficacy Results From MAHALO Study

34. Lampalizumab Phase 3 Trials CHROMA and SPECTRI

35. Stem Cell Therapy for Atrophic AMD

36. hESC RPE Phase 1/2 Study Surgical Approach

38. Concluding Remarks

39. Abbreviations

40. Abbreviations (cont)

41. Abbreviations (cont)